CTXR Past Earnings image   This CTXR past earnings page last updated 8/15/2022
CTXR Past Earnings
PeriodPast Earnings DateGAAP
Q3 20228/11/2022-0.060
Q2 20225/12/2022-0.050
Q1 20222/10/2022-0.060
Q4 202112/15/2021-0.030
Q3 20218/12/2021-0.050
Q2 20215/13/2021-0.040
Q1 20212/11/2021-0.150
Q4 202012/16/2020-0.070
Q3 20208/14/2020-0.110
Q2 20205/14/2020-0.130
Q1 20202/13/2020-0.150
Q4 201912/16/2019-0.160
CTXR Past Revenue
PeriodPast Earnings DateGAAP
Q3 20228/11/2022NA
Q2 20225/12/2022NA
Q1 20222/10/2022NA
Q4 202112/15/2021NA
Q3 20218/12/2021NA
Q2 20215/13/2021NA
Q1 20212/11/2021NA
Q4 202012/16/2020NA
Q3 20208/14/2020NA
Q2 20205/14/2020NA
Q1 20202/13/2020NA
Q4 201912/16/2019NA
Quotes delayed 20 minutes

Email EnvelopeFree CTXR Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Citius Pharmaceuticals (CTXR) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

CUE Past Earnings
CUTR Past Earnings
CVRX Past Earnings
CVS Past Earnings
CWBR Past Earnings
CYCC Past Earnings
CYCN Past Earnings
CYH Past Earnings
CYT Past Earnings
CYTH Past Earnings

CTXR Past Earnings Q&A

What was the best and worst CTXR past earnings results?
For Citius Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest CTXR past earnings result in our data set was -0.030/share posted in Q4 2021, while the lowest was in Q4 2019 when CTXR posted -0.160/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2022 when CTXR reported NA in revenue, while the quarter with the lowest revenue in our data set was Q3 2022 at NA of revenue.

  Suggested answer: There are 12 CTXR past earnings results in our data set.

On this page we presented the CTXR past earnings date information for Citius Pharmaceuticals. Reviewing that CTXR Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2021, when CTXR posted gaap of -0.030/share. Meanwhile the lowest CTXR past earnings result was in Q4 2019, when CTXR posted gaap of -0.160/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2022 when CTXR reported NA in revenue, while the smallest revenue quarter was Q3 2022 when CTXR reported NA in revenue.

Any self directed investor doing their due diligence on CTXR or any other given stock can benefit from researching all of the Citius Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Citius Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CTXR. Thanks for visiting, and the next time you need to research CTXR past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: SAM Price Target, APPH Options Chain, Top Ten Hedge Funds Holding GLBR.

 

CTXR Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.